TEM vs. VTRS: Tempus AI vs. Viatris Stock Comparison
How do Tempus AI (TEM) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Tempus AI (TEM) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but TEM is classified in Life Sciences Tools & Services while VTRS is classified in Pharmaceuticals.
Viatris (VTRS) carries decades of public-market history since March 17, 1980, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the VTRS side.
| Profile Item | TEM | VTRS |
|---|---|---|
| Name | Tempus AI Inc Class A Common Stock | Viatris Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 13.87 billion USD | 22.83 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 14, 2024 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | TEM | VTRS |
|---|---|---|
| Total Return (1Y) | 16.25% | 108.98% |
| Total Return (3Y, Annualized) | -- | 36.75% |
| Total Return (5Y, Annualized) | -- | 11.59% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Viatris (VTRS) is closer to market-like at 0.86 — a noticeable difference in market-sensitivity profile.
| Metric | TEM | VTRS |
|---|---|---|
| Volatility (1Y, Annualized) | 76.08% | 32.53% |
| Beta (5Y) | 3.34 | 0.86 |
| Max Drawdown (5Y) | -59.76% | -45.69% |
| Avg. Volume (3M) | 7.20M | 8.87M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | TEM | VTRS |
|---|---|---|
| Sharpe Ratio (1Y) | 0.16 | 3.22 |
| Sortino Ratio (1Y) | 0.26 | 5.63 |
Profitability
ROE (TTM)
Both Tempus AI (TEM) at -37.55% and Viatris (VTRS) at -4.21% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-37.55%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- TEM
- -37.55%
- Q1
- -64.05%
- Min
- -167.77%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.21%
- Max
- 109.18%
- Q3
- 6.23%
- VTRS
- -4.21%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Tempus AI (TEM) at -12.54% and Viatris (VTRS) at -4.13% report negative net margin values, usually indicating net losses over the period.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.54%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- TEM
- -12.54%
- Min
- -17.05%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.13%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- VTRS
- -4.13%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Viatris (VTRS) reports 13.85%, ranking against industry peers normally.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-13.82%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- TEM
- -13.82%
- Q1
- -78.82%
- Min
- -207.40%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.85%
- Max
- 83.12%
- Q3
- 14.77%
- VTRS
- 13.85%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | TEM | VTRS |
|---|---|---|
| ROE (TTM) | -37.55% | -4.21% |
| ROA (TTM) | -7.36% | 2.91% |
| Net Margin (TTM) | -12.54% | -4.13% |
| Operating Margin (TTM) | -13.82% | 13.85% |
| Gross Margin (TTM) | 64.46% | 41.13% |
Growth
Revenue Growth
Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Viatris (VTRS) at -2.98% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
Neither Tempus AI (TEM) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | TEM | VTRS |
|---|---|---|
| Revenue Growth (YoY) | 83.41% | -2.98% |
| Revenue Growth (3Y CAGR) | 58.29% | -4.20% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.61
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- TEM
- 2.61
- Q1
- 2.47
- Min
- 0.10
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VTRS
- 1.55
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but TEM is more stretched: Viatris (VTRS) at 0.99 sits in the higher-leverage quartile and Tempus AI (TEM) at 2.86 is above its industry benchmark range.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- TEM
- 2.86
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.99
- Max
- 1.42
- VTRS
- 0.99
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | TEM | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 2.61 | 1.55 |
| Debt / Equity (MRQ) | 2.86 | 0.99 |
| Net Debt / EBITDA | -- | 2.64 |
Dividends
Dividend Yield (TTM)
Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.53%
- VTRS
- 2.53%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Tempus AI (TEM) pays no dividend (payout 0.00%).
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
960.00%
- VTRS
- 960.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | TEM | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.53% |
| Dividend Payout Ratio (TTM) | 0.00% | 960.00% |
Valuation
P/E Ratio (TTM)
Neither Tempus AI (TEM) nor Viatris (VTRS) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- TEM
- --
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- VTRS
- --
P/S Ratio (TTM)
Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.19
- Max
- 58.18
- Q3
- 25.77
- TEM
- 9.19
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- VTRS
- 1.55
- Min
- 0.01
P/B Ratio (MRQ)
Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile relative to book while Tempus AI (TEM) at 27.66 prices above its industry range — a wide valuation gap against assets.
TEM
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.66
- TEM
- 27.66
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- VTRS
- 1.67
- Min
- -5.59
Valuation Metrics
| Metric | TEM | VTRS |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 9.19 | 1.55 |
| P/B Ratio (MRQ) | 27.66 | 1.67 |
| Free Cash Flow Yield (TTM) | 0.30% | 13.84% |